First organisation in Ireland to win preventive cardiology international accreditation imt.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imt.ie Daily Mail and Mail on Sunday newspapers.
New research could change how doctors treat some patients with high blood pressure
New research led by a professor at NUI Galway is set to change how doctors treat some patients with high blood pressure - a condition that affects more than one in four men and one in five women.
The study by researchers at NUI Galway, Johns Hopkins University and Harvard Medical School found no evidence that diastolic blood pressure - the bottom reading on a blood pressure test - can be harmful to patients when reduced to levels that were previously considered to be too low.
Lead researcher Bill McEvoy, Professor of Preventive Cardiology at NUI Galway and a Consultant Cardiologist at University Hospital Galway, said the findings have the potential to immediately influence the clinical care of patients.
HDL Anti-inflammatory Effects Show Prognostic Potential medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Loading video.
VIDEO: Video explaining the findings of the research by Professor Bill McEvoy and the research team based in Harvard Medical School and Johns Hopkins. view more
Credit: NUI Galway
New research led by a professor at NUI Galway is set to change how doctors treat some patients with high blood pressure - a condition that affects more than one in four men and one in five women.
The study by researchers at NUI Galway, Johns Hopkins University and Harvard Medical School found no evidence that diastolic blood pressure - the bottom reading on a blood pressure test - can be harmful to patients when reduced to levels that were previously considered to be too low.
email article
One thing an SGLT2 won t do? Dapagliflozin (Farxiga) flopped for hospitalized COVID-19 patients in the phase III DARE-19 trial. Full results are coming at the American College of Cardiology meeting. (
Pharmaphorum)
Johnson & Johnson s COVID vaccine is now the center of attention for rare thrombotic events. (FDA)
Post-discharge anticoagulation for COVID-19 patients was associated with 46% lower risk of major thromboembolism or death in one hospital system s registry data. (
Blood)
Kaiser Health News.
Journal of the American College of Cardiology)
Medtronic has a class I recall out on Evera, Viva, Brava, Claria, Amplia, Compia, and Visia ICDs and CRT-Ds due to short circuiting that depletes the battery, sometimes in just 1 day, the FDA cautioned.